Efficacy of trabectedin for the treatment of liposarcoma

References

• Le VH, Inai M, Williams RM, et al. Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics. Nat Prod Rep. 2015;32(2):328–347.
   PubMed Web of Science ®Google Scholar
• Peugniez C, Cousin S, Penel N. Trabectedin is an effective second-line treatment in soft tissue sarcoma patients. Ann Oncol. 2016;27(3):551–552.
   PubMed Web of Science ®Google Scholar
• Angarita FA, Cannell AJ, Abdul Razak AR, et al. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study. BMC Cancer. 2016;16(1):30.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Sarcoma: adult soft tissue cancer. [cited 2016 Apr 27]. Available from: http://www.cancer.org/cancer/sarcoma-adultsofttissuecancer/detailedguide/sarcoma-adult-soft-tissue-cancer-key-statistics
   Google Scholar
• Fletcher CDM. The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. Histopathology. 2014;64(1):2–11.
   PubMed Web of Science ®Google Scholar
• Brasfield RD, Das Gupta TK. Liposarcoma. CA Cancer J Clin. 1970;10(1):3–8.
   Google Scholar
• Shmookler B, Bickesl J, Jelinek J, et al. Bone and soft-tissue sarcomas: epidemiology, radiology, pathology and fundamentals of surgical treatment. Basel: Springer International Publishing AG; 2001.
   Google Scholar
• Zager GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy; an analysis of 1225 patients. Cancer. 2003;97(10):2530–2543.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Matsumine A, Matsubara T, et al. Retrospective analysis of metastatic sarcoma patients. Oncol Lett. 2011;2(2):315–318.
   PubMed Web of Science ®Google Scholar
• Weiss SW, Goldblum JR. Enzinger and Weiss’s soft tissue tumors. 4th ed. St Louis (MO): Mosby; 2001.
   Google Scholar
• Kane JM, Finley JW, Driscoll D, et al. The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases. Sarcoma. 2002;6(2):69–73.
   PubMedGoogle Scholar
• Pollock RE, Karnell LH, Menck HR, et al. The national cancer data base report on soft tissue sarcoma. Cancer. 1996;78(10):2247–2257.
   PubMed Web of Science ®Google Scholar
• Casali PG, Blay JY, Bertuzzi A, et al. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl3):iii102–iii112.
   PubMedGoogle Scholar
• Weiser MR, Downey RJ, Leung HY, et al. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg. 2000;191(2):184–190.
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology: soft tissue sarcoma. Version 1. 2015 [cited 2016 Apr 27]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
   Google Scholar
• Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated wat a single institution. Cancer. 2007;109(12):2522–2531.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629–1637.
   PubMed Web of Science ®Google Scholar
• Manji GA, Singer S, Koff A, et al. Application of molecular biology to individualize therapy for patients with liposarcoma. Am Soc Clin Oncol Educ Book. 2015;213–218.
   PubMedGoogle Scholar
• Liao Y, Feng Y, Shen J, et al. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma. Cancer Metastasis Rev. 2016;36(2):151–163.
   Web of Science ®Google Scholar
• Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007;67:6626–6636.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104:1862–1868.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31(16):2024–2028.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves new therapy for certain types of advanced soft tissue sarcoma. [cited 2016 Apr 27]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468832.htm
   Google Scholar
• European Medicines Agency. Yondelis, trabectedin. [cited 2016 Apr 27]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000773/human_med_001165.jsp
   Google Scholar
• D’Incalci M, Galmarini CM. A review of trabectedin (et-743): a unique mechanism of action. Mol Cancer Ther. 2010;9:2157–2163.
   PubMed Web of Science ®Google Scholar
• Guirouilh-Barbat J, Redon C, Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the mre11-rad50-nbs1 complex. Mol Biol Cell. 2008;19:3969–3981.
   PubMed Web of Science ®Google Scholar
• Martínez-Serra J, Maffiotte E, Martín J, et al. Yondelis® (et-743, trabectedin) sensitizes cancer cell lines to cd95-mediated cell death: new molecular insight into the mechanism of action. Eur J Pharmacol. 2011;658:57–64.
   PubMed Web of Science ®Google Scholar
• Dossi R, Frapolli R, Di Giandomenico S, et al. Antiangiogenic activity of trabectedin in liposarcoma: involvement of host timp-1 and timp-2 and tumor thrombospondin-1. Int J Cancer. 2015;136:721–729.
   PubMed Web of Science ®Google Scholar
• D’Incalci M, Badri N, Galmarini CM, et al. Trabectedin, a drug acting on both cancer cells and the tumor microenvironment. Br J Cancer. 2014;111(4):646–650.
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23(2):249–262.
   PubMed Web of Science ®Google Scholar
• Forni C, Minuzzo M, Virdis E, et al. Trabectedin (et-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8:449–457.
   PubMed Web of Science ®Google Scholar
• Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001 Mar 1;19(5):1256–1265.
   PubMed Web of Science ®Google Scholar
• Chuk MK, Aikin A, Whitcomb T, et al. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2012;59(5):865–869.
   PubMed Web of Science ®Google Scholar
• Ueda T, Kakunaga S, Ando M, et al. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Invest New Drugs. 2014;32(4):691–699.
   PubMed Web of Science ®Google Scholar
• van Kesteren C, Twelves C, Bowman A, et al. Clinical pharmacology of the novel marine-derived anticancer agent ecteinascidin-743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs. 2002;13(4):381–393.
   PubMed Web of Science ®Google Scholar
• Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer. 2003;39(13):1842–1851.
   PubMed Web of Science ®Google Scholar
• Lau L, Supko JG, Blaney S, et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children’s Oncology Group study. Clin Cancer Res. 2005;11(2 Pt 1):672–677.
   PubMed Web of Science ®Google Scholar
• Forouzesh B, Hidalgo M, Chu Q, et al. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res. 2009 15;15(10):3591–3599.
   PubMed Web of Science ®Google Scholar
• Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002;8(1):75–85.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin-743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001;7(2):231–242.
   PubMed Web of Science ®Google Scholar
• Machiels J-P, Staddon A, Herremans C, et al. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. Cancer Chemother Pharmacol. 2014;74:729–737.
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008;63(1):181–188.
   PubMed Web of Science ®Google Scholar
• Kasper B, Reichardt P, Pink D, et al. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG). Mar Drugs. 2015;13(1):379–388.
   PubMed Web of Science ®Google Scholar
• von Mehren M, Bookman M, Meropol NJ, et al. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol. 2015;75(5):1047–1055.
   PubMed Web of Science ®Google Scholar
• von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with PEGylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008;19(10):1802–1809.
   PubMed Web of Science ®Google Scholar
• Blay J-Y, von Mehren M, Samuels BL, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res. 2008 Oct 15;14(20):6656–6662.
   PubMed Web of Science ®Google Scholar
• Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer Res. 2009;45(7):1153–1161.
   PubMed Web of Science ®Google Scholar
• Gore L, Rivera E, Basche M, et al. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs. 2012;30(5):1942–1949.
   PubMed Web of Science ®Google Scholar
• Vidal L, Magem M, Barlow C, et al. Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Invest New Drugs. 2012;30(2):616–628.
   PubMed Web of Science ®Google Scholar
• Sessa C, Cresta S, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer. 2009;45(12):2116–2122.
   PubMed Web of Science ®Google Scholar
• Sessa C, Del Conte G, Christinat A, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. Invest New Drugs. 2013;31(5):1236–1243.
   PubMed Web of Science ®Google Scholar
• Chu Q, Mita A, Forouzesh B, et al. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res. 2010;16(9):2656–2665.
   PubMed Web of Science ®Google Scholar
• Le Cense A, Judson I, Maki R, et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer. 2013;109(7):1717–1724.
   PubMed Web of Science ®Google Scholar
• Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer. 2006;42(10):1484–1490.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, López-Pousa A, Poveda A, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs. 2012;30(2):729–740.
   PubMed Web of Science ®Google Scholar
• Grosso F, D’Incalci M. Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin. Tumori. 2011;97(2):256–25.
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22:890–899.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480–1490.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23(3):576–584.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23(24):5484–5492.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188–4196.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Domont J, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol. 2015;16(3):312–319.
   PubMed Web of Science ®Google Scholar
• Bui-Nguyen B, Butrynski JE, Penel N, et al. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer. 2015;51(10):1312–1320.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Bui N, Bonvalot S, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012;23(3):771–776.
   PubMed Web of Science ®Google Scholar
• Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16(4):406–416.
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Chevreau C, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015;16(4):457–464.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786–793.
   PubMed Web of Science ®Google Scholar
• Blay J-Y, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014;50(6):1137–1147.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–3132.
   PubMed Web of Science ®Google Scholar
• Maki R, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25(19):2755–2763.
   PubMed Web of Science ®Google Scholar
• Bay J-O, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer. 2006;119(3):706–711.
   PubMed Web of Science ®Google Scholar